Table 2.

Summary of tumor response

Response, n (%)SCC of the anus, n = 26SCCHN, n = 57sqNSCLC, n = 16All dose-expansion cohorts, N = 101a
Complete response (CR)1 (4)0 (0)0 (0)1 (1)
Confirmed partial response (PR)3 (12)3 (5)0 (0)6 (6)
Stable disease (SD)11 (42)25 (44)9 (56)45 (45)
 SD for ≥3 months6 (23)16 (28)7 (44)29 (29)
Progressive disease7 (27)21 (37)5 (31)35 (35)
Missingb4 (15)8 (14)2 (13)14 (14)
Overall response (CR+PR)4 (15)3 (5)0 (0)7 (7)
Clinical benefit rate (CR+PR+SD)15 (58)28 (49)9 (56)52 (51)
  • Abbreviations: N, population size; n, number of patients in group.

  • aTwo patients, one with SCC of the skin and one with vaginal SCC, were only included in the total dose-expansion population cohort.

  • bMissing patients discontinued from study treatment at or before cycle 3 and had no postbaseline radiologic tumor assessment.